You Had Preeclampsia. Nobody Told You What Comes Next.

She went home six days after delivery with her baby, a blood pressure prescription, and a six-week follow-up appointment. Nobody used the words “cardiovascular event.” Nobody said her lifetime heart disease risk had just doubled. Nobody said a cardiologist should be in her future. The six-week postpartum visit addressed mood, contraception, and breastfeeding. It did not address her heart.

The Mechanism

Pregnancy is a cardiovascular stress test of extreme physiologic magnitude. Cardiac output increases by 40 percent. Blood volume expands by 50 percent. The placenta makes sustained, high-volume demands on the maternal vasculature for months. Normal vasculature accommodates these demands without generating hypertension. Vasculature that carries pre-existing endothelial dysfunction, insulin resistance, or subclinical inflammatory burden does not.

Preeclampsia is defined as new-onset hypertension after 20 weeks of gestation, with blood pressure above 140/90 on two separate occasions. It often comes with proteinuria, and in more severe presentations, thrombocytopenia, impaired liver or kidney function, new headache, or visual disturbances. Delivery is the only cure. Preeclampsia complicates approximately 5 to 8 percent of pregnancies in the United States, with substantially higher rates in Black women, in women with pre-existing hypertension, obesity, or diabetes, and in first pregnancies. 5 / Solid

The mechanisms linking preeclampsia to future cardiovascular disease run in two parallel tracks, and both are operative.

The first is shared predisposition. Women who develop preeclampsia frequently carry pre-existing endothelial dysfunction, insulin resistance, or inflammatory predisposition that was not clinically apparent before pregnancy. Those same underlying conditions are the substrate for coronary artery disease, stroke, and hypertension later in life. The preeclampsia and the future cardiac event share a common vascular biology, not simply a coincidental association.

The second is direct injury from the preeclamptic episode itself. Systemic oxidative stress during the preeclamptic period injures endothelium beyond the placental bed. Sustained hypertension during the episode causes structural changes to the left ventricle, specifically concentric hypertrophy and reduced diastolic compliance, that do not fully reverse after delivery. Post-preeclamptic women measured years later show higher aortic stiffness and higher pulse wave velocity than women who had uncomplicated pregnancies, even after blood pressure normalization. The vascular aging that occurred during the preeclamptic episode does not simply undo itself.

These two mechanisms amplify each other. A woman who was already vascular-vulnerable had a pregnancy that both exposed that vulnerability and accelerated the arterial disease process. The risk trajectory after discharge is not flat.

What the Evidence Shows

The foundational dataset is the 2007 meta-analysis by Bellamy and colleagues, published in the British Medical Journal. Bellamy et al. pooled data from 28 prospective studies covering more than 3.4 million women and quantified the long-term cardiovascular signal after preeclampsia with a precision that had not previously been available. The findings: women who had preeclampsia carried a 2-fold higher risk of coronary artery disease, a 2-fold higher risk of stroke, a 4-fold higher risk of hypertension, and approximately a 2-fold higher overall cardiovascular mortality compared to women with uncomplicated pregnancies. 5 / Solid

These are not attenuated associations driven by confounding. Bellamy et al. explicitly examined whether the associations were explained by shared risk factors and found residual risk after adjustment. The preeclamptic pregnancy itself carries independent cardiovascular signal, not merely the background biology that set the stage for it.

The risk is not concentrated in a distant future. In the first 6 to 12 weeks postpartum, stroke risk is elevated, and the risk of postpartum hypertensive emergency is highest. Within the first 1 to 5 years, approximately 20 to 30 percent of women who had preeclampsia develop chronic hypertension. At 10 to 30 years, premature coronary artery disease becomes manifest relative to uncomplicated-pregnancy peers. The cumulative cardiovascular mortality difference grows across a lifetime.

The clinical recognition of this evidence is now codified in major guidelines. NICE (National Institute for Health and Care Excellence) guidelines and the American Heart Association’s 2011 scientific statement on cardiovascular disease prevention in women both identify prior preeclampsia as a modifier of lifetime cardiovascular risk that should be documented and incorporated into every future risk assessment. The guidance exists. The obstetrician-to-primary-care handoff that would operationalize it almost never happens.

What also does not happen: standard cardiovascular risk calculators, including the Framingham Risk Score and the Pooled Cohort Equations, do not include preeclampsia history as an input variable. A woman with prior preeclampsia submits her age, cholesterol, blood pressure, and smoking status, and the calculator produces a risk estimate that cannot see her most important cardiovascular modifier. She leaves the conversation labeled low risk. She is not.

Recurrence in Subsequent Pregnancies and Aspirin Prevention

A woman who had preeclampsia in one pregnancy does not return to baseline obstetric risk. Her risk of preeclampsia in a subsequent pregnancy is approximately 20 to 25 percent — roughly five to ten times the background population rate. That recurrence risk is not uniform. Women whose preeclampsia was early-onset, defined as onset before 34 weeks of gestation, carry higher recurrence risk and higher lifetime cardiovascular risk than women whose preeclampsia appeared at term. The earlier the onset, the more severe the underlying placental dysfunction and the more pronounced the long-term vascular signal.

The clinical trial that changed obstetric management of high-risk women is the ASPRE trial, published in the New England Journal of Medicine in 2017. ASPRE enrolled women identified as high-risk for preeclampsia through a first-trimester screening algorithm combining uterine artery Doppler, mean arterial pressure, and serum placental growth factor. Women randomized to low-dose aspirin starting at 11 to 14 weeks of gestation showed a 62 percent reduction in preterm preeclampsia compared to placebo. 5 / Solid Both ACOG and NICE now recommend low-dose aspirin for women at elevated risk of preeclampsia, and a prior episode of preeclampsia is among the clearest qualifying criteria.

The implication for clinical practice is specific: if a woman who has had preeclampsia becomes pregnant again, she must be identified in the first trimester — before 16 weeks — so that aspirin prophylaxis can be initiated at the appropriate gestational window. Initiating aspirin at 20 weeks does not replicate the ASPRE benefit. The identification that needs to happen at 11 to 14 weeks cannot happen if the prior preeclampsia is not in the medical record. This is one of the most concrete downstream consequences of the documentation gap described elsewhere in this article.

Beyond aspirin, blood pressure surveillance in a subsequent pregnancy after prior preeclampsia should be more intensive than standard prenatal care. Uterine artery Doppler performed at 20 to 24 weeks can identify persistent impaired placentation — a marker of which women remain at highest risk for recurrence — and may prompt earlier intervention planning. A woman planning another pregnancy after preeclampsia should have this conversation with her obstetrician before conception, not at the first prenatal visit. The preconception visit is the appropriate moment to review recurrence risk, discuss aspirin timing, establish blood pressure targets, and ensure that the prior history is correctly documented in a form that will transfer to whoever manages the next pregnancy.

The Monitoring Cadence Over the Years

The cardiovascular implications of preeclampsia do not resolve after the postpartum period, but they also do not arrive all at once. What is needed is a staged monitoring cadence appropriate to the accumulating risk over time — not a single follow-up visit and not the absence of a plan.

Immediately postpartum (6-week visit). Blood pressure must be formally assessed at the six-week postpartum visit, and if it is elevated, it should be treated — not re-measured at twelve weeks. The six-week visit is also the appropriate moment for a direct, documented conversation about lifetime cardiovascular implications. Most women are discharged from obstetric care without that conversation, which means it falls to whoever sees the patient next. If the six-week blood pressure is normal, it should be documented and the patient should know that normalization at six weeks does not eliminate long-term risk.

Years 1 to 5. Annual blood pressure measurement is the minimum appropriate surveillance. A fasting lipid panel should be obtained at least every two to three years in this window, more frequently if values are borderline. Fasting insulin or HOMA-IR should be assessed at least once to establish a metabolic baseline, because insulin resistance — which is common in post-preeclamptic women — is an independent contributor to both hypertension progression and coronary risk. Preeclampsia history should be explicitly carried forward in the active problem list at every care transition during this period. If a woman switches primary care physicians, changes insurance, or relocates, the preeclampsia history needs to follow her in a form that any new provider can see without reading the full obstetric record.

Years 5 to 10. If any cardiometabolic marker becomes elevated during this window — blood pressure trending above 130/80, LDL above 130, fasting glucose approaching impaired fasting range, or hs-CRP persistently elevated — a preventive cardiology consultation is appropriate even in the absence of symptoms. 4 / Promising This is also the window in which ApoB and Lp(a) should be measured at baseline if they have not been obtained previously. Both are more predictive of atherosclerotic cardiovascular disease than LDL alone, and both are particularly informative in women whose standard risk calculator output underestimates true risk.

10 or more years post-preeclampsia. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly lists prior preeclampsia among the risk-enhancing factors that clinicians should use to prompt discussion of preventive therapy when standard risk calculator output does not cross a treatment threshold. At this stage, a woman in her mid-forties with prior preeclampsia is in the highest-yield window for cardiovascular intervention — the years before subclinical atherosclerosis becomes clinical disease. Standard risk calculators will continue to underestimate her risk unless the clinician applies the risk-enhancing factor adjustment manually. 5 / Solid

At perimenopause. Blood pressure frequently rises at the menopause transition due to hormonal and autonomic changes. In a woman with prior preeclampsia, new or worsening hypertension at perimenopause should prompt immediate treatment rather than watchful waiting. The prior preeclampsia history shifts the context: this is not incident hypertension in an otherwise low-risk person. It is hypertension layered on top of pre-existing vascular injury, occurring at a moment when cardiovascular risk is already accelerating.

The value of this cadence is cumulative. Each stage of intervention — a treated blood pressure elevation at year two, a statin started at year seven, a preventive cardiology consultation at year nine — reduces the compound cardiovascular risk that builds from the underlying vascular biology first exposed during the preeclamptic pregnancy. The preeclampsia did not end at delivery. The monitoring should not end there either.

What to Do This Week

1. Get your preeclampsia documented as a permanent cardiovascular risk modifier. At your next clinical encounter, whether with your obstetrician, primary care physician, or any other provider, ask specifically: “Has my preeclampsia history been entered in my medical record as a lifelong cardiovascular risk modifier?” It should appear in your problem list, not buried in an obstetric note. If it is not there, ask for it to be added. This documentation affects how every future provider should approach your risk calculation.

2. Establish a blood pressure monitoring plan with a specific threshold. Target below 130/80. If readings are consistently above that level, the question is not whether to monitor more closely but when to start treatment. Ask your physician: “What number should trigger a call or a medication conversation, given my preeclampsia history?” Home blood pressure monitoring (two readings, same arm, two minutes apart, morning and evening) provides the most reliable data and should be discussed at your next visit.

3. Request a baseline cardiovascular risk lab panel. This should include a fasting lipid panel with LDL and HDL, ApoB (once, to establish baseline), Lp(a) (once, as a genetic baseline that does not change), fasting insulin or HOMA-IR to assess insulin resistance, and high-sensitivity CRP. If any values are elevated, the combination of an abnormal metabolic marker with prior preeclampsia history warrants preventive cardiology or internal medicine consultation, not observation.

4. Make the lifestyle interventions that have the strongest cardiovascular outcome data. Blood pressure control is the most important single modifiable factor. The intervention with the strongest evidence for reducing hypertension recurrence and cardiovascular events in this population is aerobic exercise at 150 minutes per week of moderate intensity. Mediterranean-pattern diet has the most consistent dietary evidence for cardiovascular protection and is the preferred dietary framework over general “heart-healthy” advice. Weight management matters because preeclampsia risk and post-preeclamptic cardiovascular risk are both substantially higher with central adiposity. Smoking cessation, if applicable, is a non-negotiable priority.

5. Ask whether your current physician’s risk calculator accounts for your history. The Framingham Risk Score and Pooled Cohort Equations do not include preeclampsia. If your physician uses one of these tools and says your cardiovascular risk is low, the appropriate follow-up is: “Does this calculator account for preeclampsia as a risk modifier? If not, how should we adjust the risk estimate?” The AHA’s 2019 Guideline on Primary Prevention of Cardiovascular Disease explicitly lists preeclampsia among the risk-enhancing factors that should prompt clinician-patient discussion about preventive treatment when the calculator alone does not cross a threshold.

Preeclampsia is the cardiovascular event that most women are never told they had. The gap between what the evidence requires and what the healthcare system delivers is real, documented, and large. You are not being excessive in asking for surveillance. You are asking for what the guidelines already recommend, and what your obstetrician likely did not have time, training, or protocol to provide before you were discharged.

For the cardiac changes that accelerate in women before menopause more broadly: Your Doctor Said You Are Safe Until Menopause.

For the intersection of Black maternal outcomes and cardiovascular risk: Black Maternal Mortality: The Cardiovascular Conversation Nobody Has.

For what the cardiovascular lab panel should include in the years following preeclampsia: The Women’s Cardiac Screening Lab Panel.